Phase Ib Clinical Study of BCMA-Targeted Chimeric Antigen Receptor T-Cell Injection (CART-BCMA) in the Treatment of Patients With Relapsed/Refractory Multiple Myeloma
Phase Ib Clinical Study of BCMA-Targeted Chimeric Antigen Receptor T-Cell Injection (CART-BCMA) in the Treatment of Patients With Relapsed/Refractory Multiple Myeloma is a EARLY_PHASE1 clinical asset sponsored by Chulalongkorn University in Relapsed/Refractory Multiple Myeloma (MM). SEO and diligence focus: Chimeric Antigen Receptor T Cells (CAR-T), endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
Indication: Relapsed/Refractory Multiple Myeloma (MM)
Modality: cell therapy
Target: Chimeric Antigen Receptor T Cells (CAR-T)
Sponsor: Chulalongkorn University
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 25, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Chimeric Antigen Receptor T Cells (CAR-T)
View original source fields
Condition raw: Relapsed/Refractory Multiple Myeloma (MM)
Condition normalized: Relapsed/Refractory Multiple Myeloma (MM)
Modality raw: cell therapy
Modality normalized: cell therapy
Target raw: Chimeric Antigen Receptor T Cells (CAR-T)
Target normalized: Chimeric Antigen Receptor T Cells (CAR-T)